Компания Radiopharm Theranostics получила обнадеживающие результаты фазы 1 клинических испытаний препарата RAD301 для лечения рака поджелудочной железы

Исследование продемонстрировало безопасный профиль препарата и его способность избирательно накапливаться в метастазах, что открывает перспективы для улучшения диагностики и терапии. На основе этих данных компания планирует переходить к фазе 2 разработки для оценки роли RAD301 в диагностическом и терапевтическом лечении.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer

Radiopharm Theranostics (RADX), a clinical-stage biopharmaceutical company developing oncology radiopharmaceuticals, announced encouraging results from its Phase 1 imaging trial of RAD301 in patients with pancreatic ductal adenocarcinoma. Trial Findings The study demonstrated a favorable safety profile and biodistribution across all participants. Imaging data showed significant and selective tumor uptake of RAD301 in Pancreatic cancer metastases, with low background uptake in organs such as the liver, lung, and bowel—areas where pancreatic cancer often spreads. These results support RAD301's potential to distinguish metastatic lesions from surrounding normal tissue. About RAD301 RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets alpha-v beta-6-integrin, a receptor highly expressed on pancreatic carcinoma cells and associated with tumor invasion and poor survival. The therapy has previously received Orphan Drug Designation from the FDA. Company Comment Riccardo Canevari, CEO and Managing Director of Radiopharm, stated that these findings mark an important step forward for patients with advanced pancreatic cancer, highlighting RAD301's potential role in improving disease detection, patient selection, and future theranostic applications. Next Steps The company plans to advance RAD301 into Phase 2 development, aiming to build on these results and explore its role in both diagnostic imaging and therapeutic applications for pancreatic cancer. RADX has trading at $2.04 and $16.25 over the past year. The stock closed Tuesday's trading at $2.12, up 1.92%. In pre-market trading the stock is at $2.20, up 3.77% For comments and feedback contact: [email protected] Business News September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.